Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lonza revenue decreased from CHF5.9 billion in 2019 to CHF4.5 billion in 2020, a (23.9%) decrease.

Annual Revenue (CHF)

Lonza revenue was CHF4.51 b in FY, 2020 which is a (23.9%) year over year decrease from the previous period.

FY, 2018FY, 2019FY, 2020
RevenueCHF5.54 bCHF5.92 bCHF4.51 b

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Lonza revenue breakdown by business segment: 25.8% from Capsules & Health Ingredients, 48.0% from Biologics, 15.5% from Small Molecules and 10.8% from Cell & Gene

FY, 2020FY, 2019FY, 2018
Specialty IngredientsCHF1.71 bCHF2.39 b
Pharma & BiotechCHF4.18 bCHF3.11 b
CorporateCHF60 mCHF38 m
Capsules & Health Ingredients1.15 b
Biologics2.15 b
Small Molecules692 m
Cell & Gene481 m
FY, 2019FY, 2018
EuropeCHF2.01 b
Latin AmericaCHF82 m
North and Central AmericaCHF2.61 b
AsiaCHF746 m
Australia & New ZealandCHF78 m
South AfricaCHF10 m
Other CountriesCHF5 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu